On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver Beyond the Headlines: FDA Warning Letters to GLP 1 Compounders Spencer Fane What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide